174 related articles for article (PubMed ID: 37490642)
21. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
22. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
23. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
Koshiro N; Nakajima K; Oyama M; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
Int J Urol; 2022 Dec; 29(12):1477-1487. PubMed ID: 36070138
[TBL] [Abstract][Full Text] [Related]
27. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
29. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
30. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
31. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract][Full Text] [Related]
32. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
[TBL] [Abstract][Full Text] [Related]
33. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
[TBL] [Abstract][Full Text] [Related]
34. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
35. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
36. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
37. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract][Full Text] [Related]
38. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
39. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
40. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
